Pomerantz Law Firm Launches Investigation into Celcuity Investors' Claims Amidst Stock Decline
On August 6, 2026, the Pomerantz Law Firm announced its investigation into potential claims by investors of Celcuity Inc., known by its NASDAQ ticker symbol CELC. The firm’s focus is to evaluate whether Celcuity and its management may have engaged in actions that constitute securities fraud or other illegal business practices that affected the company’s valuation and investors’ interests.
The backdrop for this investigation stems from a press release issued by Celcuity on July 14, 2026, which informed the public that the U.S. Food and Drug Administration (FDA) granted approval for their innovative breast cancer treatment, Revtorpyk (gedatolisib). However, the announcement included a timeline for commercial launch that was notably later than what many analysts anticipated, with sales expected to commence in the late third quarter of 2026. Notable analysts, including Stifel’s Stephen Wiley and Leerink’s Andrew Berens, expressed concerns that this delayed timeline was unexpected and could impact stockholder confidence.
Following the announcement, the market reacted swiftly; Celcuity’s stock plummeted by $19.54 per share, marking a steep decline of 17.6%, which pushed the closing share price down to $91.51 by the end of trading on July 15, 2026. Investors found themselves caught in a troubling situation as the company's earlier expectations did not align with the FDA's approval timeline, raising questions about the transparency and communication of the company's management.
Pomerantz LLP, a law firm with a long-standing reputation in the field of securities litigation, is well-versed in handling cases involving corporate misfeasance. Founded by Abraham L. Pomerantz, the firm has been an advocate for shareholders for over 85 years, recovering extensive damages for those adversely affected by corporate wrongdoing. Investors who believe they might be eligible for participation in potential legal actions against Celcuity are encouraged to contact Pomerantz’s team. Particularly, Danielle Peyton can be reached at the provided email and phone number for those seeking further information or wishing to join an existing class action.
The details of the investigation and its eventual outcomes remain to be seen, but it highlights the critical importance of corporate governance and the potential hazards of investing in companies that may not fully disclose significant operational changes and their implications in a timely manner. Investors are urged to stay informed and assess their options carefully as this story develops.
For more information regarding your rights as an investor in Celcuity Inc. or to share your experience, please reach out to Pomerantz LLP. Advocacy and support for investor rights remain the firm's primary focus as they navigate this pressing situation surrounding Celcuity Inc.
The backdrop for this investigation stems from a press release issued by Celcuity on July 14, 2026, which informed the public that the U.S. Food and Drug Administration (FDA) granted approval for their innovative breast cancer treatment, Revtorpyk (gedatolisib). However, the announcement included a timeline for commercial launch that was notably later than what many analysts anticipated, with sales expected to commence in the late third quarter of 2026. Notable analysts, including Stifel’s Stephen Wiley and Leerink’s Andrew Berens, expressed concerns that this delayed timeline was unexpected and could impact stockholder confidence.
Following the announcement, the market reacted swiftly; Celcuity’s stock plummeted by $19.54 per share, marking a steep decline of 17.6%, which pushed the closing share price down to $91.51 by the end of trading on July 15, 2026. Investors found themselves caught in a troubling situation as the company's earlier expectations did not align with the FDA's approval timeline, raising questions about the transparency and communication of the company's management.
Pomerantz LLP, a law firm with a long-standing reputation in the field of securities litigation, is well-versed in handling cases involving corporate misfeasance. Founded by Abraham L. Pomerantz, the firm has been an advocate for shareholders for over 85 years, recovering extensive damages for those adversely affected by corporate wrongdoing. Investors who believe they might be eligible for participation in potential legal actions against Celcuity are encouraged to contact Pomerantz’s team. Particularly, Danielle Peyton can be reached at the provided email and phone number for those seeking further information or wishing to join an existing class action.
The details of the investigation and its eventual outcomes remain to be seen, but it highlights the critical importance of corporate governance and the potential hazards of investing in companies that may not fully disclose significant operational changes and their implications in a timely manner. Investors are urged to stay informed and assess their options carefully as this story develops.
For more information regarding your rights as an investor in Celcuity Inc. or to share your experience, please reach out to Pomerantz LLP. Advocacy and support for investor rights remain the firm's primary focus as they navigate this pressing situation surrounding Celcuity Inc.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.